Literature DB >> 19126566

VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection.

K Engels1, A du Bois, P Harter, A Fisseler-Eckhoff, F Kommoss, R Stauber, M Kaufmann, V Nekljudova, S Loibl.   

Abstract

AIMS: Clinical stage at the time of diagnosis and achievement of complete macroscopic resection during initial surgery are key factors determining the outcome of ovarian cancer. However, prediction of outcome lacks accuracy and more reliable prognostic factors are required. Therefore, an analysis and evaluation of key angiogenic factors was carried out to determine their diagnostic and prognostic value in serous ovarian cancer.
METHODS: Expression levels of vascular endothelial growth factor (VEGF)-A, hypoxia-inducible factor (HIF)1-alpha and inducible nitric oxide synthase (i-NOS) were analysed by immunohistochemistry in a homogenous group of 112 patients with serous adenocarcinoma of the ovary. Vascular density as an indicator of angiogenesis was assessed using the Chalkley eyepiece method after staining for CD34. The correlation of these data with survival and established prognostic factors such as histological grade, Federation of Gynecology and Obstetrics (FIGO) stage, and residual tumour after surgery, was evaluated. Survival analyses, multivariate analyses and correlation tests were performed.
RESULTS: In the patient group with macroscopic complete tumour resection (R0) there was a significant correlation between VEGF-A and i-NOS expression. Kaplan-Meier analysis further revealed improved progression-free survival for R0 patients with VEGF-A-positive and i-NOS-negative tumours. The predictive relevance of VEGF-A regarding progression-free survival was sustained in multivariate analysis using FIGO stage, grading and resection status as fixed variables.
CONCLUSION: VEGF-A and i-NOS are prognostic markers for clinical outcome in serous ovarian cancer patients with macroscopic complete tumour resection (R0). Hence, pre-therapeutic assessment of VEGF-A as predictive factor for an antiangiogenic therapy might be of clinical value.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19126566     DOI: 10.1136/jcp.2008.063859

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  13 in total

1.  Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.

Authors:  Chelsea Bolyard; Ji Young Yoo; Pin-Yi Wang; Uksha Saini; Kellie S Rath; Timothy P Cripe; Jianying Zhang; Karuppaiyah Selvendiran; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

2.  Impact of Secretion-Active Osteoblast-Specific Factor 2 in Promoting Progression and Metastasis of Head and Neck Cancer.

Authors:  Désirée Gül; Andrea Schweitzer; Aya Khamis; Shirley K Knauer; Guo-Bin Ding; Laura Freudelsperger; Ioannis Karampinis; Sebastian Strieth; Jan Hagemann; Roland H Stauber
Journal:  Cancers (Basel)       Date:  2022-05-09       Impact factor: 6.575

3.  Vascular endothelial growth factor (VEGF) polymorphism and increased risk of epithelial ovarian cancer.

Authors:  José Augusto Rinck-Junior; Cristiane Oliveira; Gustavo Jacob Lourenço; Regina Aparecida Martinho Sagarra; Sophie Françoise Mauricette Derchain; José Getulio Segalla; Carmen Silvia Passos Lima
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-05       Impact factor: 4.553

Review 4.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

5.  High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.

Authors:  Minna Sopo; Hanna Sallinen; Kirsi Hämäläinen; Annukka Kivelä; Seppo Ylä-Herttuala; Veli-Matti Kosma; Leea Keski-Nisula; Maarit Anttila
Journal:  PLoS One       Date:  2020-11-05       Impact factor: 3.240

6.  Cytokines as Prognostic Biomarkers of Epithelial Ovarian Cancer (EOC): A Systematic Review and Meta-Analysis.

Authors:  Moh Nailul Fahmi; Heru Pradjatmo; Indwiani Astuti; Ricvan Dana Nindrea
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

7.  Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.

Authors:  Afshin Amini; Samar Masoumi Moghaddam; David L Morris; Mohammad H Pourgholami
Journal:  J Oncol       Date:  2011-09-26       Impact factor: 4.375

8.  The homeoprotein DLX4 controls inducible nitric oxide synthase-mediated angiogenesis in ovarian cancer.

Authors:  Bon Trinh; Song Yi Ko; Dhwani Haria; Nicolas Barengo; Honami Naora
Journal:  Mol Cancer       Date:  2015-04-30       Impact factor: 27.401

9.  Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.

Authors:  Qiaoling Sun; Jinghong Zhou; Zheng Zhang; Mingchuan Guo; Junqing Liang; Feng Zhou; Jingwen Long; Wei Zhang; Fang Yin; Huaqing Cai; Haibin Yang; Weihan Zhang; Yi Gu; Liang Ni; Yang Sai; Yumin Cui; Meifang Zhang; Minhua Hong; Junen Sun; Zheng Yang; Weiguo Qing; Weiguo Su; Yongxin Ren
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

10.  Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.

Authors:  Cécile Le Page; David G Huntsman; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Cancers (Basel)       Date:  2010-05-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.